TITLE

HIV Infection and Hepatic Enzyme Abnormalities: Intricacies of the Pathogenic Mechanisms

AUTHOR(S)
Pol, Stanislas; Lebray, Pascal; Vallet-Pichard, Anaïs
PUB. DATE
March 2004
SOURCE
Clinical Infectious Diseases;3/1/2004 Supplement, Vol. 38, pS65
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Liver enzyme elevations are common in human immunodeficiency virus (HIV)-infected patients, and their diagnosis or management may be difficult because of the intricacies of the pathogenic mechanisms involved. These include hepatotoxicity related to the highly active antiretroviral therapy (HAART) regimen, idiosyncratic or immunoallergic mechanisms, and direct cytotoxicity enhanced by an underlying liver disease. Liver enzyme abnormalities may also reflect hepatitis B (HBV) or hepatitis C (HCV) infection, which each have their own risks for chronic immune-mediated liver disease (including hepatitis flare after immune reconstitution) and of direct cytotoxicity. Finally, other factors may affect liver deterioration, including alcohol-related liver disease, nonalcoholic steatohepatitis associated with metabolic syndromes (e.g., hyperlipidemia, diabetes, or being overweight) that are potentially HAART related, and use of medication or illicit drugs (e.g., methamphetamine). A better understanding of these complex interactions, including adjustments of dosages of antiretroviral drugs, will probably help in the management of HIV-infected patients with liver enzyme abnormalities.
ACCESSION #
12355638

 

Related Articles

  • Hepatotoxicidade associada aos anti-retrovirais. Valente, C.; Fernandes, C. // RPDI - Revista Portuguesa de Doenças Infecciosas;set-dez2011, Vol. 7 Issue 3, p118 

    Liver-related complications in human immunodeficiency virus-injected patients are increasing in the highly active anti-retroviral therapy era and liver toxicity is a frequent cause of morbidity, mortality and treatment discontinuation. The contribution of each drug to liver toxicity is difficult...

  • Hepatotoxicity of Antiretroviral Drugs in HIV Seropositive Nigerian Patients. Emejulu, A. A.; Ujowundu, C. O.; Igwe, C. U.; Ouwuliri, V. A. // Australian Journal of Basic & Applied Sciences;2010, Vol. 4 Issue 9, p4275 

    Hepatotoxicity of antiretroviral (ARV) drugs using liver function parameters were assessed in 40 HIV seropositive subjects on ARV, 40 HIV seropositive subjects not on ARV and another 40 HIV seronegative subjects. They were all of the same age range of 19 - 56 years old. Results show that the...

  • Antiretroviral Therapy Does Not Block the Secretion of the Human Immunodeficiency Virus Tat Protein. Mediouni, Sonia; Darque, Albert; Baillat, Gilbert; Ravaux, Isabelle; Dhiver, Catherine; Tissot-Dupont, Herv�; Mokhtari, Malika; Moreau, Herv�; Tamalet, Catherine; Brunet, Corinne; Paul, Pascale; Dignat-George, Fran�oise; Stein, Andreas; Brouqui, Philippe; Spector, Stephen A.; Campbell, Grant R.; Loret, Erwann P. // Infectious Disorders - Drug Targets;Feb2012, Vol. 12 Issue 1, p81 

    Tat is a viral protein secreted from HIV infected cells and extra cellular Tat is suspected to prevent destruction of HIV infected cells from cells of the cellular immunity. The effect of anti retroviral therapy (ART) on Tat secretion has never been investigated. In this study, we tested for...

  • Antiretroviral Therapy and HIV/Hepatitis B Virus Coinfection. Benhamou, Yves // Clinical Infectious Diseases;3/1/2004 Supplement, Vol. 38, pS98 

    Among human immunodeficiency virus (HIV)-infected individuals, the prevalence of hepatitis B surface antigen (HBsAg) seropositivity is ∼10-fold higher than in the general population. HIV/hepatitis B virus (HBV)coinfected patients have an increased risk of cirrhosis and liver-disease-related...

  • Hepatic Safety. Dieterich, Douglas T. // Clinical Infectious Diseases;3/1/2004 Supplement, Vol. 38, pS43 

    Presents a summary of the presentations made during the "Hepatic Safety and HAART" conference held in Santa Barbara, California on June 7 to 9, 2002. Aim of the event to review the effects of antiretroviral drugs on liver; Account of the mechanisms responsible for drug-induced liver injury;...

  • Pitfalls of Assessing Hepatotoxicity in Trials and Observational Cohorts. Sabin, Caroline A. // Clinical Infectious Diseases;3/1/2004 Supplement, Vol. 38, pS56 

    The relationship between the use of antiretroviral drugs and the development of hepatic abnormalities has been documented in both randomized controlled trials (RCTs) and observational database studies. Both types of study design are known to have limitations when addressing this issue. Whereas...

  • Outcomes among Patients with End-Stage Liver Disease Who Are Coinfected with HIV and Hepatitis C Virus. Neff, Guy W.; Shire, Norah J.; Rudich, Steven M. // Clinical Infectious Diseases;7/1/2005 Supplement, Vol. 41, pS50 

    In at-risk populations, shared routes of transmission lead to high rates of concordance between infection with human immunodeficiency virus (HIV) type 1 and hepatitis C virus (HCV). In the era of highly active anti-retroviral therapy (HAART), end-stage liver disease (ESLD) has emerged as a...

  • Influence of Liver Fibrosis Stage on Plasma Levels of Antiretroviral Drugs in HIV-Infected Patients with Chronic Hepatitis C. Barreiro, Pablo; Rodríguez-Novoa, Sonia; Labarga, Pablo; Ruiz, Andrés; Jiménez-Nácher, Inmaculada; Martín-Carbonero, Luz; Gonzalez-Lahoz, Juan; Soriano, Vincent // Journal of Infectious Diseases;4/1/2007, Vol. 195 Issue 7, p973 

    Background. Most antiretrovirals are metabolized in the liver, and lower dosing could be advisable in patients with severe liver insufficiency. Methods. Plasma drug levels were measured in hepatitis C virus (HCV)/human immunodeficiency virus (HIV)-coinfected patients receiving nevirapine (NVP),...

  • Lessons From HIV Therapy Applied to Viral Hepatitis Therapy: Summary of a Workshop. Monto, Alexander; Schooley, Robert T; Lai, Jennifer C; Sulkowski, Mark S; Chung, Raymond T; Pawlotsky, Jean-Michel; McHutchison, John G; Jacobson, Ira M // American Journal of Gastroenterology;May2010, Vol. 105 Issue 5, p989 

    Therapies for hepatitis B virus (HBV) have continued to evolve, and new therapies for hepatitis C virus (HCV) will soon be available in clinical practice. These medications for hepatitis C will mark the first time that direct antivirals that target HCV functions have been used. When such drugs...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics